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depression (3.5%) was mostly unchanged (Baseline-Wk8; P =
0.059). Clinical depression (patient-reported) was associated
with increased bothersomeness of other symptoms (fatigue, loss
of appetite, nervousness) at Baseline & Wk8 (P < 0.05). CON-
CLUSIONS: Patient-reported depression outcomes should be
valued during HIV treatment, as more patients who were viro-
logically controlled but experiencing Grade 2 PI/NNRTI-
associated side effects self-reported signs of clinical depression
than were diagnosed by physicians. Prevalence of clinical depres-
sion was reduced following substitution to LPV/r.
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OBJECTIVES: The widespread use of highly active antiretrovi-
ral therapy (HAART) has greatly prolonged life expectancy in
patients with HIV. Therefore, health-related quality of life
(HRQoL) has become an increasingly important endpoint in
clinical trials to assess interventions for people with HIV. We
reviewed the HRQoL measures that have been used in HIV/AIDS
since 1990 to establish the most appropriate measures to use in
future research and clinical trials. METHODS: A comprehen-
sive, unbiased review of generic and HIV-speciﬁc HRQoL mea-
sures was conducted using predeﬁned selection criteria. Generic
and HIV-speciﬁc measures were assessed for practicality (length,
administration time and mode). Generic measures were also
assessed for their ability to elicit utility data and provide nor-
mative values. Measures of HRQoL that were considered prac-
tical and were capable of producing utility data and normative
values (generic measures) were assessed in detail in terms of their
psychometric properties, patient derived content (HIV-speciﬁc
measures), and use in clinical trials. RESULTS: Two generic mea-
sures (EuroQol ﬁve Dimension [EQ-5D] and Medical Outcomes
Study [MOS] Short Form 36 [SF-36]) and six HIV-speciﬁc mea-
sures met the initial selection criteria and were reviewed in full.
EQ-5D and SF-36 were very similar in terms of the selection cri-
teria and two HIV-speciﬁc measures (Functional Assessment of
HIV Infection [FAHI] and MOS-HIV) were selected on the basis
of their superior psychometric properties. CONCLUSIONS: We
recommend using either the EQ-5D with the MOS-HIV, or the
SF-36 with the FAHI to assess HRQoL in HIV/AIDS patients
when planning future research. Administration of these measures
in combination would enable utility scores to be calculated,
patient scores to be compared with normative data, and disease-
speciﬁc HRQoL to be assessed. Future research should concen-
trate on the sensitivity of the different measures at each stage of
infection in patients on HAART.
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OBJECTIVES: To validate a symptom assessment instrument for
patients with acute bacterial sinusitis (ABS). METHODS: Data
were obtained from a randomized, double-blind, equivalency
study of adults with radiographic evidence of ABS treated with
telithromycin 800mgod for 5 days (n = 159) or moxiﬂoxacin
400mgod for 10 days (n = 163). A 5-item Acute Sinusitis Daily
Symptom Survey (ASDSS) was developed for use in the trial. The
ﬁve items of the ADSS (nasal congestion, runny nose, postnasal
discharge, thick nasal discharge, and facial pain/pressure) used a
six-point adjectival scale ranging from zero (“no problem”) to
ﬁve (“problem as bad as it can be”). Overall ASDSS score was
the sum of item responses. Subjects completed the ASDSS daily
for the ﬁrst 17 days of the study. At Visits 1 (Day 1) 2 (Day 3–5),
and 4 (Day 17–24), subjects were assessed for quality of life (SF-
36, acute form), treatment outcomes (success/failure), and infec-
tion-related signs/symptoms. Data were pooled across treatment
groups. RESULTS: Survey completion rates ranged from 100%
(Day 3) to 79.8% (Day 17). Pearson correlations between the
ASDSS items ranged from 0.258 to 0.639. Test-retest intraclass
correlation coefﬁcients (ICC) measured over a 5 day interval
(Day 1–5) were: nasal congestion (0.681), runny nose (0.612),
postnasal discharge (0.689), thick nasal discharge (0.669), and
facial pain/pressure (0.679). Cronbach’s alpha was 0.788 and
test-retest reliability (ICC) of the total score was 0.694. Pearson
correlations between ASDSS and the SF-36 scales at Visit 4
ranged from -0.293 (mental health) to -0.496 (vitality). Pearson
correlations with the ASDSS at Visit four were 0.599 for major
and 0.634 for minor symptoms of infection. Mean ASDSS scores
at Visit four were 3.34 for subjects deemed treatment successes
and 10.35 for treatment failures (F = 2.60, p < 0.0001). CON-
CLUSIONS: The ASDSS appears to be a valid symptom assess-
ment instrument for patients with ABS.
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OBJECTIVES: In the mountain kingdom of Nepal, nearly
44,000 new cases of the tuberculosis (TB) appear every year. This
study explores community valuation of TB prevention by esti-
mating household and community willingness to pay (WTP) for
the prevention of transmission and treatment of TB in the rural
areas of mid-Nepal. METHODS: A contingent valuation survey
was used to assess individual WTP for speciﬁc prevention and
treatment interventions for TB. In order to estimate conﬁdence
limits in mean WTP and to generate a distribution of WTP for
the community, accounting for uncertainty in regression coefﬁ-
cients and variability within the population, a two-dimensional
Monte Carlo simulation was also developed. RESULTS: The
study results show a mean WTP of $0.81 per month per house-
hold (90% CL: $0.43, $1.61) to prevent transmission of TB.
However, the mean WTP for TB treatment was estimated to be
$2.31 per month (90% CL: $1.32, $3.47) per household. Nearly
22% and 47% of household were not willing to pay for pre-
vention and treatment of TB, respectively. As expected, income
positively affected estimates of mean WTP for both TB treatment
and prevention. An individual’s familiarity with TB and super-
stitions signiﬁcantly negatively inﬂuenced WTP for treatment
and prevention. Contrary to expectation, WTP for TB treatment
and prevention was not inﬂuenced by religion and ethnicity in
the rural villages of Nepal. In our study, sex and health educa-
tion do not show any signiﬁcant affects on WTP for transmission
prevention and treatment interventions of TB. CONCLUSIONS:
These results show that the majority of the community places a
positive value on both prevention and treatment of TB. Mean
